Focus: Purdue Pharma is a specialty pharmaceutical company headquartered in Stamford, CT, focused on small-molecule therapeutics in neurology. The company is heavily dependent on legacy opioid and CNS products, with OxyContin representing 94% of revenue.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Purdue Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Purdue Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Purdue Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship product representing 94% of company revenue, but faces imminent patent cliff in 2030 with significant loss-of-exclusivity risk.
Local anesthetic with approaching patent cliff and minimal commercial prominence.
Early-stage antibiotic in pre-launch phase with no reported revenue; represents portfolio diversification attempt.
CNS stimulant with robust patent protection through 2038; represents best-positioned product for long-term sustainability.
Sleep medicine in peak commercialization with intermediate patent expiration approaching in 2029.
8 discontinued, 1 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
+2 more